Partner Christopher Betti was quoted in a Law360 article that discusses how, despite predictions to the contrary, biologic and biosimilar companies have not significantly altered their practices in exchanging patent information since the Purple Book Continuity Act of 2021 made such data public.
Christopher emphasized that companies have not withheld patent information as expected, noting that "from the few biosimilar litigations that we've analyzed over the last two years, it's really not showing us that the brand holders have held back," adding that initial expectations of them "trying to hide the ball a bit" haven't materialized.